Tipifarnib, in particular, has gained renewed interest as a potential treatment for HRAS-mutant cancers [134] and as part of combination therapy with KRAS G12C inhibitors, such as sotorasib, demonstrating synergistic effects in preclinical lung adenocarcinoma models [135]. Here, KRAS is linked to cancer.